Mode
Text Size
Log in / Sign up
N/A N=46 Treatment

Vertos Mild - Post Market Patient Outcomes

Lumbar Spinal Stenosis

Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Pain as Measured by Visual Analog Scale (VAS). — 2.17 units on a scale — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Minimally Invasive Lumbar Decompression (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The Center for Pain Relief, Inc.
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain as Measured by Visual Analog Scale (VAS).
2.17 <0.0001 sig
SECONDARY
Improvement in Functional Mobility
13.43 <0.0001 sig
SECONDARY
Quality of Life as Measured by the Symptom Severity Scale of the Zurich Claudication Questionnaire (ZCQ).
1.07
SECONDARY
Quality of Life as Measured by Physical Function Scale of the Zurich Claudication Questionnaire (ZCQ).
0.59

Summary

This is a single-center study evaluating the outcomes of patients with painful lumbar spinal stenosis who were treated with the mild procedure (minimally invasive lumbar decompression. The patients will be followed for 6 months after the procedure.

Eligibility Criteria

Inclusion Criteria

  • Symptomatic and lumbar spinal stenosis caused by dorsal element hypertrophy
  • Prior failure of conservative therapy and Oswestry Disability Index (ODI) >20%
  • Radiologic evidence of lumbar spinal stenosis, ligamentum flavum hypertrophy (typically >2.5mm),confirmed by pre-op MRI/CT report
  • Central canal cross sectional area clearly reduced per MRI/CT report
  • If present, anterior listhesis < or = to 5.0mm (preferred) and deemed stable by the Investigator
  • Able to walk at least 10 feet unaided before being limited by pain
  • Available to complete 26 weeks of follow up
  • A signed Consent Form is obtained from the patient
  • Adults 18 years of age or older

Exclusion Criteria

  • Prior surgery at the intended treatment level
  • Compound fracture with intraspinal retropulsion contributing to spinal stenosis
  • Disabling back or leg pain from causes other than lumbar spinal stenosis
  • Disc protrusion or osteophyte formation severe enough to confound study outcome
  • Facet hypertrophy severe enough to confound study outcome
  • Bleeding disorders and/or current use of anti-coagulants
  • Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment
  • Epidural steroids with 3 weeks prior to procedure
  • Inability of patient to lie prone for any reason with anesthesia support
  • Metabolic wound healing pathologies that may be deemed by the Investigator to compromise the study outcomes
  • Dementia and/or inability to give informed consent
  • Pregnant and/or breastfeeding
  • On workman's Compensation or considering litigation associated with back pain
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01076244). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search